These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 16489039

  • 1. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
    Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS.
    Cancer Res; 2006 Feb 15; 66(4):2338-45. PubMed ID: 16489039
    [Abstract] [Full Text] [Related]

  • 2. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
    Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS.
    Cancer Res; 2003 Nov 15; 63(22):7900-6. PubMed ID: 14633719
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN.
    Clin Cancer Res; 2005 Dec 01; 11(23):8467-75. PubMed ID: 16322310
    [Abstract] [Full Text] [Related]

  • 4. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y, Takano H, Nagao S, Fojo T.
    Jpn J Cancer Res; 2001 Sep 01; 92(9):968-74. PubMed ID: 11572765
    [Abstract] [Full Text] [Related]

  • 5. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
    Matsumoto Y, Takano H, Fojo T.
    Cancer Res; 1997 Nov 15; 57(22):5086-92. PubMed ID: 9371507
    [Abstract] [Full Text] [Related]

  • 6. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
    Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS.
    Blood; 2001 Sep 15; 98(6):1897-903. PubMed ID: 11535527
    [Abstract] [Full Text] [Related]

  • 7. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
    Lage H, Dietel M.
    J Cancer Res Clin Oncol; 2002 Jul 15; 128(7):349-57. PubMed ID: 12136248
    [Abstract] [Full Text] [Related]

  • 8. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
    Pu QQ, Bezwoda WR.
    Anticancer Res; 2000 Jul 15; 20(4):2569-78. PubMed ID: 10953328
    [Abstract] [Full Text] [Related]

  • 9. The association of up-regulation of X-linked inhibitor of apoptosis protein with cell adhesion-mediated drug resistance in U937 cells.
    Wang X, Wang C, Qin YW, Yan SK, Gao YR.
    Hematol Oncol; 2008 Mar 15; 26(1):21-6. PubMed ID: 17721914
    [Abstract] [Full Text] [Related]

  • 10. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
    Emmons M, Boulware D, Sullivan DM, Hazlehurst LA.
    Biochem Pharmacol; 2006 Jun 28; 72(1):11-8. PubMed ID: 16678798
    [Abstract] [Full Text] [Related]

  • 11. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.
    Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS.
    Cancer Res; 1999 Mar 01; 59(5):1021-8. PubMed ID: 10070958
    [Abstract] [Full Text] [Related]

  • 12. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ, Li TK, Chan YL, Hsin LW, Liao CH, Lee CH, Lyu PC, Guh JH.
    Biochem Pharmacol; 2008 Feb 15; 75(4):847-56. PubMed ID: 18035333
    [Abstract] [Full Text] [Related]

  • 13. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA.
    Cancer Chemother Pharmacol; 2004 Feb 15; 53(2):155-62. PubMed ID: 14504921
    [Abstract] [Full Text] [Related]

  • 14. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
    Lage H, Helmbach H, Dietel M, Schadendorf D.
    Br J Cancer; 2000 Jan 15; 82(2):488-91. PubMed ID: 10646909
    [Abstract] [Full Text] [Related]

  • 15. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
    Elliott SL, Crawford C, Mulligan E, Summerfield G, Newton P, Wallis J, Mainou-Fowler T, Evans P, Bedwell C, Durkacz BW, Willmore E.
    Br J Haematol; 2011 Jan 15; 152(1):61-71. PubMed ID: 21083655
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
    Skladanowski A, Côme MG, Sabisz M, Escargueil AE, Larsen AK.
    Mol Pharmacol; 2005 Sep 15; 68(3):625-34. PubMed ID: 15942022
    [Abstract] [Full Text] [Related]

  • 17. Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage.
    Smith PJ, Sykes HR, Fox ME, Furlong IJ.
    Cancer Res; 1992 Jul 15; 52(14):4000-8. PubMed ID: 1617677
    [Abstract] [Full Text] [Related]

  • 18. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
    Gray MD, Mann M, Nitiss JL, Hendershot LM.
    Mol Pharmacol; 2005 Dec 15; 68(6):1699-707. PubMed ID: 16141312
    [Abstract] [Full Text] [Related]

  • 19. Chromosome mediated gene transfer of drug resistance to mitoxantrone.
    Hazlehurst LA, Gros P, Dalton WS.
    Anticancer Res; 1998 Dec 15; 18(2A):1005-10. PubMed ID: 9615755
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
    Snapka RM, Gao H, Grabowski DR, Brill D, Chan KK, Li L, Li GC, Ganapathi R.
    Biochem Biophys Res Commun; 2001 Feb 02; 280(4):1155-60. PubMed ID: 11162648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.